What You Should Know:
- The Centers for Disease Control and Prevention (CDC) has recently released its Fentanyl Study Dashboard, an innovative tool that utilizes data from the Toxicology Investigators Consortium (ToxIC), to track and monitor nonfatal overdose trends associated with fentanyl.
- The dashboard, “Fentalog Study: A Subset of Nonfatal Suspected Opioid-Involved Overdoses with Toxicology Testing” went live in May of 2023 aims to provide vital insights to healthcare professionals, policymakers, and researchers, enabling them to respond effectively to the ongoing opioid crisis.
The ToxIC Fentalog Study
The ToxIC Fentalog Study collects data from 10 geographically diverse hospitals in 9 states to identify risk factors and evaluate optimal treatments for nonfatal overdoses involving fentanyl, fentalogs, illicit benzodiazepines, and adulterants (such as xylazine). Now in its 4th year, the study has over 1300 cases that are utilized to characterize synthetic opioids used, evaluate treatments, and track regional trends in fentalog overdoses.
The American College of Medical Toxicology (ACMT) Toxicology Investigators Consortium (ToxIC) Fentanyl Analog Study, also known as the Fentalog Study, is a five-year initiative (2020-2025) conducted through a National Institute on Drug Abuse RO1 grant (NIDA R01DA048009) at the Icahn School of Medicine at Mount Sinai. It examines the clinical effects of fentanyl analogs among suspected opioid overdoses and utilizes ToxIC’s extensive network of healthcare facilities to aggregate and analyze nonfatal overdose data.
